Study |
Men(%) |
Men(%) |
LA size |
LA size |
LVEF% |
LVEF% |
CHADS2 score |
CHADS2 score |
CHA2DS2-VASc score |
CHA2DS2-VASc score |
Hypertension, n
(%) |
Hypertension, n (%) |
Diabetes, n (%) |
Diabetes, n (%) |
Heart failure, n (%) |
Heart failure, n (%) |
Leong-Sit
|
179/232
(77%)
|
372/438
(85%)
|
4.2±0.7
|
4.4±0.7
|
58±10
|
58±9
|
0 (0, 1)
|
1 (0, 1)
|
NG
|
NG
|
50 (22%)
|
189 (43%)
|
7 (3.0%)
|
25 (5.7%)
|
5
(2.2%)
|
18
(4.1%)
|
Julian Chun |
83.6% |
66.0% |
NG |
NG |
NG |
NG |
0.3 ± 0.6 |
0.9 ±
0.8 |
NG |
NG |
24.9% |
61.6% |
2.0% |
8.5% |
NG |
NG |
Lamyaa Allam
|
23/30
(76.6 %)
|
34/46
(73.9%)
|
39.6 ± 3.1
|
52.8 ± 4.9
|
65.6 ± 3.2
|
64.2 ± 4.5
|
NG
|
NG
|
0.93 ± 0.75
|
2.11 ± 1.32
|
15 (50%)
|
28 (60.9%)
|
5 (16.6%)
|
10 (21.7%)
|
1 (3.3%)
|
5 (10.8%)
|
Leonard Bergau
|
78/93
(83.9%)
|
(82/114)
72%
|
36.0 ± 6.6
|
38 ± 5
|
53.7 ± 5.3
|
54 ± 3
|
NG
|
NG
|
0.3 ± 0.7
|
0.98 ± 0.9
|
12 (13%)
|
NG
|
1 (1%)
|
NG
|
NG
|
NG
|
Maxime Tijskens
|
162 /197(82%)
|
363 /554(66%)
|
40.9 ± 6.2
|
44.2 ± 7.2
|
60.3±8.6
|
58.5 ±11.2
|
NG
|
NG
|
0.54 ±0.8
|
1.9 ±
1.4
|
21%
|
46%
|
2%
|
10%
|
9%
|
17%
|
Michael Ghannam |
69(84%) |
NG |
39±7 |
NG |
0.55±0.11 |
NG |
NG |
NG |
NG |
NG |
13 (16) |
NG |
3 (4) |
NG |
NG |
NG |